Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

The Swedish innovation model: “There is a paradox”

It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?

Nytt läkemedel ska förenkla behandling av blödarsjuka

En ny typ av behandling mot hemofili, som bara behöver ges varannan månad, har godkänts av den amerikanska läkemedelsmyndigheten FDA.

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

Life science trends 2025 – Part 1 obesity drugs

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

Tanklock för dina tankar

I vårt sortiment erbjuder vi ett brett utbud av trycklösa luckor från vår tillverkare Zimmerlin. Luckorna görs i hög kvalité utefter de höga renlighetskrav som ...

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

A modular system for precise and automated cell dispensing

How the benefits of laboratory automation can be combined with gentle cell handling.

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

GSK acquires oncology research company

GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Reduced heat transfer to the media with media-separated valves

In laboratory automation, many liquids are used that react sensitively to heat. One possible factor for the transfer of heat to the fluid are media-separated so...

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

Mångmiljardaffär i jakten på nästa blockbuster inom cancer

Bristol Myers Squibb betalar upp till 11,1 miljarder dollar, motsvarande 106 miljarder kronor, för att köpa in sig i en av de hetaste läkemedelskandidaterna inom immunonkologi.